by Gonzalo Payan | Aug 7, 2025
MAX BioPharma, Inc. and Revilico, Inc. announced their collaboration in studying the mechanisms of action, performing lead optimization, and identifying the molecular targets of MAX BioPharma’s oxysterol-based drug candidates using a state-of-the-art,...by Gonzalo Payan | Aug 4, 2025
MAX BioPharma Reports on Oxy210’s Inhibition of Hepatic Expression of Senescence-Associated, Pro-Fibrotic, and Pro-Inflammatory Genes in Mice During Development of MASH and in Hepatocytes In Vitro. Read the full study...by Gonzalo Payan | Jun 14, 2025
MAX BioPharma reports on the Inhibition of Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells by its Oxysterol Drug Candidate, Oxy210 Paper available from https://pubmed.ncbi.nlm.nih.gov/39404395/by Gonzalo Payan | Feb 21, 2025
https://www.prnewswire.com/news-releases/metaba-and-max-biopharma-announce-breakthrough-progress-on-next-generation-oxysterol-based-antibiotics-302379559.html?tc=eml_cleartime...by Gonzalo Payan | Feb 14, 2025
MAX BioPharma in collaboration with Metaba will be presenting at Biocom California’s 15th Annual Global Life Science Partnering & Investor Conference scheduled for February 25th – February 28th in La Jolla,...